A Single and Multiple Ascending Dose Trial of KT-474 in Healthy Adult Volunteers and Patients With Atopic Dermatitis (AD) or Hidradenitis Suppurativa (HS)

• ClinicalTrials.gov Identifier: NCT04772885
• Recruitment Status: Completed
• First Posted: February 26, 2021
• Last Update Posted: October 24, 2022
• Sponsor: Kymera Therapeutics, Inc.
• Information provided by (Responsible Party): Kymera Therapeutics, Inc.

Study Description

Brief Summary:

KT-474 is an oral heterobifunctional small molecule IRAK4 degrader being developed for the treatment of interleukin-1 receptor (IL-1R)/toll-like receptor (TLR)-driven immune-inflammatory diseases. This first-in-human (FIH) study will characterize the safety, tolerability and the pharmacokinetics/pharmacodynamics (PK/PD) of a single ascending dose and multiple ascending doses of KT-474 in healthy volunteers and patients with atopic dermatitis (AD) or hidradenitis suppurativa (HS). The effects of food on the absorption of KT-474 will also be evaluated in healthy volunteers.

Condition or disease	Intervention/treatment	Phase
Healthy Volunteer; Atopic Dermatitis; Hidradenitis Suppurativa	Drug: KT-474/Placebo; Drug: KT-474	Phase 1

Detailed Description:

This is a first-in-human (FIH), Phase 1 randomized, placebo-controlled, single and multiple ascending dose trial of KT-474 that will characterize the safety, PK and PD of orally administered KT-474 after a single dose (Part A) and after repeated dosing first in healthy adult volunteers (Part B) and then in patients with AD or HS (Part C). Initially, a dose range of KT-474 in single ascending dose (SAD) escalation cohorts will be explored in healthy subjects. Up to five single dose cohorts of healthy subjects is also planned to understand food effects (FE) on the PK of KT-474. Enrollment of healthy subjects into 2-week multiple ascending dose (MAD) escalation cohorts will be initiated once sufficient safety and PK data from multiple SAD cohorts are available to inform the safe starting dose for the 2-week MAD portion of the study. After the MAD portion in healthy subjects is completed, the safety, PK, and PD of a dose of KT-474 that was found to be safe in healthy subjects when administered for 2 weeks will then be evaluated in AD or HS subjects for 28 days of dosing. Separately, additional multiple dose cohorts evaluating once every other day and/or twice weekly dosing schedules at or below previously evaluated dose levels in healthy volunteers may be initiated.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 154 participants
• Allocation: Randomized
• Intervention Model: Sequential Assignment
• Intervention Model Description: Single ascending dose escalation and multiple ascending dose escalation study followed by an evaluation of food effects on absorption
• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
• Masking Description: randomized double blind (for Parts A and B only)
• Primary Purpose: Treatment
• Official Title: A Phase 1 Randomized, Placebo-controlled, Single and Multiple Ascending Dose Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Orally Administered KT-474 in Healthy Adult Volunteers and Patients With Atopic Dermatitis (AD) or Hidradenitis Suppurativa (HS)
• Actual Study Start Date: February 23, 2021
• Actual Primary Completion Date: October 20, 2022
• Actual Study Completion Date: October 20, 2022

Arms and Interventions

Arm	Intervention/treatment
Experimental: Single ascending dose cohorts in healthy subjects; Healthy volunteer subject cohorts randomized 6:2 receiving a single dose of KT-474 or placebo. The first cohort will receive 25 mg of KT-474 or placebo. Dose escalation will occur if KT-474 or placebo is tolerated.	Drug: KT-474/Placebo; KT-474 or matching placebo oral tablet(s)
Experimental: Multiple ascending dose cohorts in healthy subjects; Healthy volunteer subject cohorts randomized 9:3 to receive KT-474 or placebo for 14 days continuous dosing. The first cohort will receive a dose of KT-474 or placebo determined to be safe based on data generated in the SAD portion.	Drug: KT-474/Placebo; KT-474 or matching placebo oral tablet(s)
Experimental: Food Effect Cohort in healthy subjects; Healthy Volunteer SAD subject cohorts (up to 5) will receive a single dose of KT-474 in the fed state.	Drug: KT-474/Placebo; KT-474 or matching placebo oral tablet(s)
Experimental: Multiple dose cohort in HS and AD patients; A single cohort of up to 30 patients with AD or HS to receive a dose of KT-474 determined to be safe based on data generated in the healthy volunteer MAD portion, dosed daily X 28 days.	Drug: KT-474; KT-474 oral tablet(s)
Experimental: Multiple dose cohorts in healthy subjects; Healthy volunteer subject cohorts randomized 9:3 to receive KT-474 or placebo every other day over 14 days, and/or twice weekly over 15 days. The first cohort will receive a dose of KT-474 or placebo determined to be safe based on data generated in the SAD and MAD portion.	Drug: KT-474/Placebo; KT-474 or matching placebo oral tablet(s)

Outcome Measures

Primary Outcome Measures :

1. Incidence and severity of treatment emergent Adverse Events [ Time Frame: up to 28 days ]
2. Incidence and frequency of use of concomitant medication [ Time Frame: up to 28 days ]

Secondary Outcome Measures :

1. Area under the curve plasma concentration from time zero to infinity [AUC(0-∞)] (single dose only) [ Time Frame: up to 28 days ]
2. Area under the curve plasma concentration from time zero to last measurable concentration [AUC(0-last)] [ Time Frame: up to 28 days ]
3. Area under the plasma concentration-time curve during a dosing interval [AUC(0-tau)] [ Time Frame: up to 28 days ]
4. Maximum observed plasma concentration (Cmax) [ Time Frame: up to 28 days ]
5. Time to maximum observed plasma concentration (Tmax) [ Time Frame: up to 28 days ]
6. Apparent clearance (CL/F) [ Time Frame: up to 28 days ]
7. Apparent volume of distribution (Vz/F) [ Time Frame: up to 28 days ]
8. Terminal elimination half-life (t1/2) [ Time Frame: up to 28 days ]
9. Mean residence time (MRT) [ Time Frame: up to 28 days ]
10. Renal clearance (CLR) [ Time Frame: up to 28 days ]

Other Outcome Measures:

1. IRAK4 levels in peripheral blood mononuclear cells [ Time Frame: up to 28 days ]
2. IRAK4 levels in skin [ Time Frame: up to 28 days ]
3. Percentage Change from baseline in Total Abscess and Inflammatory Nodule (AN) Count, Skin Pain Numerical Rating Scale (NRS), Peak pruritis NRS, and HS Physician's Global Assessment (HS-PGA) in HS patients [ Time Frame: up to 42 days ]
4. Percentage Change from baseline in Eczema Area and Severity Index (EASI), Peak Pruritus Numerical Rating Scale (NRS) and Investigator Global Assessment (IGA) in AD patients [ Time Frame: up to 42 days ]

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 55 Years (Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: Yes

Criteria

Healthy Volunteer (Parts A and B) Inclusion Criteria:

1. Male and female subjects, including female subjects of child bearing potential, between the ages of 18 and 55 with a weight at least 50 kg and a body mass index (BMI) between 18.0 and 30.0 kg/m2.
2. Subjects confirmed as negative in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection test at Screening and on Day -2.
3. Evidence of a personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the study.
4. Agreement and ability to comply with all contraception requirements if applicable.
5. All subjects must be willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.

Healthy Volunteer (Parts A and B) Exclusion Criteria:

1. Evidence or history of a clinically significant medical condition or other condition that might significantly interfere with the absorption, distribution, metabolism, or excretion of study drug, or place the subject at an unacceptable risk as a participant in this study.
2. Healthy volunteers who have a clinically relevant history or presence of respiratory, GI, renal, hepatic, hematological, lymphatic, neurological, cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological, dermatological, or connective tissue diseases or disorders.
3. Healthy volunteers who have any known factor, condition, or disease that might interfere with treatment compliance, study conduct or interpretation of the results such as drug or alcohol dependence or psychiatric disease.
4. Female Healthy volunteers who are pregnant, trying to become pregnant or lactating or breastfeeding.
5. Healthy volunteers who have participated in any investigational drug or device clinical study within 3 months prior to first dosing on this study.
6. Healthy volunteers who have previously participated in a study with an investigational product or device involving the dosing of a biological targeted at any immune pathway within 1 year prior to Screening.

AD or HS Patient (Part C) Inclusion Criteria:

1. Male or female patients aged 18 years to 55 years (inclusive) at the time of Screening, and in generally good health, except for AD or HS, and has a BMI of 17.5 to 35.0 kg/m2; and a total body weight >50 kg (110 lb).
2. Diagnosis of AD or HS for at least 6 months.
3. Patients with AD: having at least 10% treatable percentage body surface area at Screening or on Admission (excluding the scalp and designated venous access areas).
4. Willingness and ability to comply with all contraception requirements as applicable based on reproductive status.
5. Has adequate venous access with venous access sites having AD-unaffected, non-infected skin to permit repeated PK sampling.
6. Female patients must have a negative result for the serum pregnancy test at the Screening Visit and on admission.
7. Evidence of a personally signed and dated informed consent document indicating that the patient has been informed of all pertinent aspects of the study.
8. Patients who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
9. Patients with HS: A total Abscess and Inflammatory Nodule count of ≥4 at baseline

AD or HS Patient (Parts C) Exclusion Criteria:

1. Has any clinically significant medical disorder, condition, disease (including active or potentially recurrent dermatological conditions other than AD or HS), significant physical examination or laboratory findings that may interfere with study objectives, in the Investigator's opinion (eg, conditions or findings that may expose a patient to unacceptable risk by study participation, confound the evaluation of treatment response or adverse events, or otherwise interfere with a patient's ability to complete the study).
2. Has an active systemic or soft tissue infection, including known actively-infected AD or HS skin lesion.
3. Treatment with an investigational product within 30 days or 5 half-lives preceding the first dose of investigational product (whichever is longer).
4. Use of prescription or nonprescription drugs including topical corticosteroids, vitaminic and dietary supplements within 14 days or 5 half-lives (whichever is longer) prior to the first dose of investigational product.
5. Blood donation (excluding plasma donations and platelet donations) of approximately ≥400 mL within 3 months or ≥200 mL within a month prior to dosing.
6. History of sensitivity to heparin or heparin-induced thrombocytopenia.
7. Unwilling or unable to comply with the protocol procedures and/or assessments.
8. Other acute or chronic medical or psychiatric condition including recent (within the past year) or active suicidal ideation or behavior or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the Investigator, would make the patient inappropriate for entry into this study.
9. Patients with HS: Fistula and Tunnel count of >20 at baseline.
10. Patients with AD: Active herpes infection or history of eczema herpeticum.

Contacts and Locations

Locations

United States, Arizona

Medical Dermatology Specialists

Phoenix, Arizona, United States, 85006

Southwest Skin Specialists 32nd St

Phoenix, Arizona, United States, 85018

Southwest Skin Specialists Tatum

Phoenix, Arizona, United States, 85028

Beatrice Keller Clinic

Sun City West, Arizona, United States, 85375

United States, Florida

Encore Medical Research, LLC. - Boynton Beach

Boynton Beach, Florida, United States, 33436

Research Centers of America

Hollywood, Florida, United States, 22024

Encore Medical Research, LLC. - Hollywood

Hollywood, Florida, United States, 33021

Encore Medical Research, LLC. - Weston

Weston, Florida, United States, 33331

United States, Kansas

Dermatology and Skin Cancer Center of Leawood

Leawood, Kansas, United States, 66211

Dermatology and Skin Cancer Center of Overland Park

Overland Park, Kansas, United States, 66223

United States, Missouri

Dermatology and Skin Cancer Center of Lee's Summit

Lee's Summit, Missouri, United States, 64064

United States, New Jersey

TKL Research

Fair Lawn, New Jersey, United States, 07410

United States, Texas

U.S. Dermatology Partners Jollyville

Austin, Texas, United States, 78759

U.S. Dermatology Partners Cedar Park

Cedar Park, Texas, United States, 78613

Sponsors and Collaborators

Kymera Therapeutics, Inc.

Investigators

• Study Director: Ashwin Gollerkeri, MD; Kymera Therapeutics, Inc.

More Information

• Responsible Party: Kymera Therapeutics, Inc.
• ClinicalTrials.gov Identifier: NCT04772885
• Other Study ID Numbers: KT474-HV-101
• First Posted: February 26, 2021
• Last Update Posted: October 24, 2022
• Last Verified: October 2022

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Kymera Therapeutics, Inc.:

Atopic Dermatitis; Hidradenitis Suppurativa; Immune-inflammatory diseases

Additional relevant MeSH terms:

Hidradenitis Suppurativa; Dermatitis, Atopic; Dermatitis; Eczema; Hidradenitis; Skin Diseases; Skin Diseases, Genetic; Genetic Diseases, Inborn; Skin Diseases, Eczematous; Hypersensitivity, Immediate; Hypersensitivity; Immune System Diseases; Sweat Gland Diseases; Skin Diseases, Bacterial; Bacterial Infections; Bacterial Infections and Mycoses; Infections; Skin Diseases, Infectious; Suppuration